miR-21 and miR-145 cooperation in regulation of colon cancer stem cells by Yingjie Yu et al.
miR-21 and miR-145 cooperation in regulation of
colon cancer stem cells
Yu et al.
Yu et al. Molecular Cancer  (2015) 14:98 
DOI 10.1186/s12943-015-0372-7
Yu et al. Molecular Cancer  (2015) 14:98 
DOI 10.1186/s12943-015-0372-7RESEARCH Open AccessmiR-21 and miR-145 cooperation in regulation of
colon cancer stem cells
Yingjie Yu1,3*, Pratima Nangia-Makker1,2,3, Lulu Farhana1,3, Sindhu G. Rajendra1, Edi Levi1
and Adhip PN Majumdar1,2,3*Abstract
Background: Acquired drug resistance is one of the major reasons for failing cancer therapies. Although the reasons
are not fully understood, they may be related to the presence of cancer stem cells (CSCs). We have reported that
chemo-resistant (CR) colon cancer cells, highly enriched in CSCs, exhibit a marked up-regulation of miR-21 and that
down-regulation of this miR renders the CR cells more susceptible to therapeutic regimens. However, the underlying
molecular mechanism is poorly understood. The aim of this investigation is to unravel this mechanism.
Methods: The levels of miR-145 and miR-21 were manipulated by transfection of mature, antago-miRs or pCMV/miR-145
expression plasmid. Quantitative RT-PCR or/and Western blots were performed to examine the expression of CD44,
β-catenin, Sox-2, PDCD4, CK-20 and k-Ras. Colonosphere formation and SCID mice xenograft studies were performed to
evaluate the tumorigenic properties of CSC-enriched colon CR cells.
Results: We investigated the role that microRNAs (miRs), specifically miR-21 and miR-145 play in regulating colon CSCs.
We found the expression of miR-21 to be greatly increased and miR-145 decreased in CR colon cancer cells that are
highly enriched in CSC, indicating a role for these miRNAs in regulating CSCs. In support of this, we found that whereas
forced expression of miR-145 in colon cancer cells greatly inhibits CSCs and tumor growth, up-regulation of miR-21 causes
an opposite phenomenon. In addition, administration of mature miR-145 or antagomir-21 (anti-sense miR-21) greatly
suppresses the growth of colon cancer cell xenografts in SCID mice. This was associated with decreased expression of
CD44, β-catenin, Sox-2 and induction of CK-20 indicating that administration of miR-145 or antagomir-21 decreases CSC
proliferation and induces differentiation. In vitro studies further demonstrate that miR-21 negatively regulates miR-145 and
vice versa. k-Ras appears to play critical role in regulation of this process, as evidenced by the fact that the absence of
k-Ras in CR colon cancer cells increases miR-145 expression, suppresses miR-21, and interrupts the negative cooperation
between miR-21 and miR-145.
Conclusions: Our current observations suggest that miR-21, miR-145, and their networks play critical roles in regulating
CSCs growth and/or differentiation in the colon cancer and progression of chemo-resistance.
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Despite advances in medicine, nearly 50% of patients with
colorectal cancer (CRC) show tumor recurrence, for which
the outcome remains poor; the median survival following
recurrence is only 13.3 months [1]. The higher recurrence
of CRC is thought to be the result of drug-resistance of
cancer cells. Although the reasons for drug resistance are* Correspondence: aa5142@wayne.edu; a.majumdar@wayne.edu
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unless otherwise stated.not fully understood, they may be related to the presence of
cancer stem or cancer stem-like cells (CSCs/CSLCs) that
are thought to play pivotal role in tumor initiation, progres-
sion, metastasis, and its relapse [2-4].
CSCs/CSLCs are a small population of self-renewing un-
differentiated cells within a tumor that have been shown to
be resistant to radiation and chemotherapy [2]. CSCs/
CSLCs isolated from different solid tumors, including the
colon are usually identified by specific surface epitopes.
Colon CSCs/CSLCs have been shown to express CD44,
CD166, CD133 and ESA (epithelial-specific antigen, alsois an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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served that in humans, colon CSCs/CSLCs are present
not only in premalignant adenomas but also in normal
appearing colonic mucosa and that the population of
CSCs/CSLCs increases with advancing age, suggesting
that they may be partly responsible for the age-related rise
in colorectal cancer [6].
The standard therapy for advanced CRC includes surgery
followed by chemotherapy or other effective therapeutic
regimen to eliminate any remaining cancer cells. 5-
Fluorouracil (5-FU) based regimen such as FOLFOX (5-FU
plus Oxaliplatin and Folinic acid) remains the backbone of
colorectal cancer chemotherapeutics but with limited suc-
cess. Near 50% tumor recurrence rate suggests that the cells
survive chemotherapy and may lead to cancer recurrence.
We have reported that 5-Fluorouracil and Oxaliplatin (FU-
Ox) resistant [chemo-resistant (CR)] colon cancer HCT116
and HT29 cells exhibit enrichment of CSCs/CSLCs, elevated
levels of mature miR-21 and that miR-21 induces stemness
in colon cancer cells [7,8].
MicroRNAs (miRNAs) comprise a broad class of small
(19–22 nucleotide) endogenous RNAs that negatively con-
trol the expression of the target genes by cleaving mRNA
or through translation repression [9], and can function as
oncogenes or tumor suppressors depending on the target.
More than 1500 human miRNAs are annotated in the
miRBase and many of them are aberrantly expressed in
several pathological conditions, including cancer. In colo-
rectal cancer, miR-21 has been reported to function as an
oncomiR (a miRNA with oncogenic properties) due to its
key role in several processes of tumor promotion, invasion
and metastasis [10,11]. We found miR-21 to induce stem-
ness of colon cancer cells [8]. Furthermore, overexpres-
sion of miR-21 has been shown to dramatically reduce the
therapeutic efficacy of 5-FU [12]. Although the underlying
mechanisms for regulation of miR-21 in CRC remain to
be defined, we reported EGFR inhibitor Cetuximab (mAb
to EGFR) to decrease its expression suggesting a role for
EGFR in regulating miR-21[13]. In contrast to miR-21,
miR-145 is a p53 regulated tumor suppressor, whose
down-regulation has been found in colorectal and other
cancers [14,15]. It regulates stem cell renewal and pluripo-
tency by suppressing multiple pluripotent genes: OCT4,
SOX2 and KLF4 [14].
Herein, we report that stable over expression of miR-
145 in colon cancer HCT-116 or HT-29 cells or in the
corresponding CR colon cancer cells significantly induces
differentiation and inhibits their growth in vitro. A similar
phenomenon occurs following down-regulation of miR-21
in CR colon cancer cells. The tumorigenic potential of
parental and CR-HT-29 cells in SCID mice was inhibited
by administration of miR-145 or anti-miR-21. In addition,
we observed downregulation of pluripotency factors Oct4,
Sox2, Nanog as well as miR-21 following overexpressionof miR-145 in colon cancer cells. We also report that miR-
21 negatively regulates miR-145 and vice versa. k-Ras ap-
pears to play critical role in the regulation of this process,
as evidenced by the fact that the absence of k-Ras in CR
colon cancer cells increases miR-145 expression, sup-
presses miR-21, and interrupts the cooperation between
miR-21 and miR-145.
Results
Over-expression of miR-145 induces differentiation, in-
hibits stemness and xenograft tumors in SCID mice
More than 80% of colorectal cancers arise from adenoma-
tous polyps that are known to contain CSCs/CSLCs [6] and
dysregulation of miRNAs [16]. We have reported that the
expression of miR-21 is greatly increased in chemo-resistant
(CR) colon cancer cells that are highly enriched in CSC, and
forced expression of miR-21 in colon cancer cells greatly in-
creases CSC population accompanied by induction of tumor
growth, indicating miR-21 regulates stemness of colon can-
cer cells [8,17].
To determine the putative functional properties of miR-
145 in the development of colorectal tumor and its relation
tomiR21 expression, pCMV/miR145 plasmid (Origene, Rock-
ville, MD) was stably transfected in HCT-116 cells. As deter-
mined by qRT-PCR (real time PCR) analysis, the expression
of miR-145 was found to be 4-fold higher in the miR-145
positive cells, compared to empty vector (Figure 1A). In
contrast, miR-21 was decreased by 50% in miR-145 overex-
pressing cells, compared to the vector-transfected control
cells (Figure 1A). Western blot analysis revealed that the
levels of Sox2, the target of miR-145 were decreased by 34%
and the expression of cytokeratin-20 (CK-20), the differen-
tiation marker was increased by 67%, compared to the
vector-transfected controls (Figure 1B).
The next set of experiments was carried out to determine
whether miR-145 may regulate stemness of colon cancer
cells. The functional property of cancer stem cells is defined
by their ability to form sphere/spheroid (in vitro) in serum-
free medium containing growth factors (stem cell medium)
when plated in ultra low-attachment plates under extreme
limited dilutions [18]. To determine whether and to what
extent miR-145 over-expression affects the sphere forming
properties of colon cancer cells, HCT-116 cells stably trans-
fected with pCMV/miR-145 or pCMV vector (control)
were subjected to an extreme limiting dilution analysis
(ELDA). Number of spheroids formed as well as the fre-
quency to form spheroids by miR-145 expressing HCT-116
cells was found to be about 88% lower than those formed
by the vector-transfected control cells (p <0.001) (Figure 1C
and Table 1). Further, the average diameter of spheroids,
obtained from miR-145 overexpressing cells, was found to
be smaller than the controls (Table 1 and Figure 1C).
Tumorigenic potential of the miR-145 overexpressing cells
was analyzed by generating xenograft tumors in SCID mice.
Figure 1 Over-expression of miR-145 in colon cancer HCT-116 cells by stably transfected pCMV/miR-145 downregulates miR-21 and induces differentiation,
inhibits stemness and produces no visible tumors in SCID mice. (A) qRT-PCR showing up-regulation of mature miR-145 and down regulation of miR-21 in
HCT-116 cells that were stably transfected with pCMV/miR-145 plasmid or the corresponding vector, *P< 0.001. (B)Western-blot showing decreased
expression of Sox2 and increased expression of CK-20 in miR-145 over-expressing HCT-116 cells, compared to the corresponding vector-transfected control
cells. β-actin was used as a loading control, (C) Representative photographs showing colonospheres formed by the cells from miR-145 expressing clones,
derived from HCT-116 cells, stably transfected with pCMV-miR-145 plasmid or the corresponding vector (top panel), histogram showing the number of
colonspheres formed by miR-145 over-expressing HCT-116 cells, compared to the corresponding vector-transfected control cells (bottom panel, *P< 0.001),
(D) while administration of miR-145 over-expressing HCT-116 cells produces no visible tumors in SCID mice, the vector-transfected HCT-116 cells (control)
induces large tumors in SCID mice. The data represent means of three independent experiments.
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vector-transfected (control) cells formed palpable tumor
within 3 weeks of injection, no tumor could be detected
with HCT-116 pCMV/miR-145 cells even after 6 weeks
(Figure 1D).
miR-145 and miR-21 cooperation plays a role in regulating
cancer stem cell proliferation and differentiation
In the next set of experiments we tested whether there is a
cooperation between miR-145 and miR-21 and how thisTable 1 Sphere-forming frequency, diameter and/or self-rene
transfected with pCMV (Vector), pCMV/miR-145 (miR-145) col
Vector
Sphere-forming frequency (95% CI) 1/11 (1/17-1/4)
Diameter (μm) 104.0 ± 18.5
Self-renewal (spheres per 200 cells) 13 ± 3
Data are pooled from three independent experiments for each. CI, confidence intercooperation may regulate cancer stem cell proliferation and
differentiation. To conduct this experiment, we utilized CR
colon cancer cells that are enriched in CSCs and exhibit a
3–5 fold increase in the precursor and mature miR-21 as
shown in Figure 2A, an observation similar to what we re-
ported earlier [8,17]. We observed that the expression of
tumor suppressive miR-145 in CR HCT-116 cells was de-
creased by 62% and in miR-21-overexpressing HCT-116
cells by 90%, when compared with their corresponding par-
ental or empty vector control cells (Figure 2A and B). Inwal ability of cells from colonospheres of stably
on cancer HCT-116 cells
miR-145 P value
1/88 (1/196-1/40) <0.001
47.0 ± 13.2 <0.001
- <0.001
val.
Figure 2 Chemo-resistance, overexpression of miR-21 and colonosphere formation in colon cancer HCT-116 cells, all of which are associated with increased
miR-21 levels, lead to down-regulation of miR-145, and miR-145 and miR-21 negatively regulate each other in chemo-resistant (CR) colon cancer cells. (A)
qRT-PCR showing up-regulation of mature miR-21 and down-regulation of mature miR-145 in CR HCT-116 cells when compared with the parental HCT-116
cells. (B) qRT-PCR showing over-expression of miR-21 (stably transfected cells) leads to decreased miR-145 compared to the vector-transfected control. (C)
qRT-PCR showing down-regulation of miR-145 and up-regulation of mature miR-21 in colonospheres formed by parental HCT-116 cells. (D) qRT-PCR showing
relative expression of miR-21 and miR-145 in CR HT-29 cells at 48 h following transfection of mature miR-145 or anti-miR-21. All the data represent means ±
SD of three independent experiments, *P< 0.001, compared to the control.
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decreased by ~70% in colonospheres formed by the parental
HCT-116 cells, the expression of miR-21 was increased
by ~180% in these colonospheres, when compared with the
corresponding parental HCT-116 cells (Figure 2C). These
results indicate that overespression of miR-21 is associated
with downregulation of miR-145 and vice versa in colon
cancer cells and that both miR-21 and miR-145 are involved
in regulating the growth of colonospheres, enriched in
CSCs.
To further investigate the cooperation between miR-145
and miR-21 in CR colon cancer cells, we regulated the
levels of miR-145 (increased) or miR-21(decreased) by
transfecting mature miR-145 or anti-miR-21 in CR-HT-29
cells in vitro. As expected, miR-145 was increased and
miR-21 was decreased after transfection of miR-145 and
anti-miR-21, compared with corresponding control in CR
colon cancer cells (Figure 2D). Following transfection of
anti-miR21 in CR-HT-29 cells, there was a marked 6-fold
increase of miR-145 (Figure 2D). On the other hand, in
miR145-transfected CR HT-29 cells, the levels of miR21
were decreased by 70%, compared to the corresponding
control (Figure 2D). Collectively, the current data suggest
a negative feedback between the tumor suppressor miR-
145 and oncomiR miR-21 in CR colon cancer cells.miR-145 and, anti-miR-21 inhibit tumorigenic potential of
chemo-resistant (CR) colon cancer HT-29 cells in SCID
mice
To determine whether and to what extent miR-145 or anti-
miR-21 would affect the tumorigenic potential, xenografts in
SCID mice formed by colon cancer parental HT-29 or CR-
HT-29 cells were first analyzed for the presence of markers
of CSCs/CSLCs and their growth and differentiation. We
observed that the expression of CD44 (colon CSC marker),
β-catenin (stem cell growth regulator) and SOX2 (a miR-
145 target) was 39%, 356% and 1600% higher, respectively,
whereas the levels of PDCD4 and CK20 were 40% and 95%
lower in CR HT-29 xenografts, when compared with the
values from xenografts of parental HT-29 cells (Figure 3).
We then determined the effectiveness of miR-145
in suppressing the growth of colon cancer xenografts in
SCID mice. HCT-116 cells have consistently active
mutated k-Ras, while HT-29 cells harbor normal k-Ras.
Additionally, endogenous miR-145 is highly repressed in
HT-29 cells, therefore, in this investigation, 2.5 × 105 CR
HT-29 cells were injected with 50% Matrigel in each
mouse. Once palpable tumors were developed (~3 weeks),
Polyethylenimines (PEI)/miRNA-145 complex treatment
(i.p.; weekly) was initiated. The results revealed that
treatment with (PEI)/miRNA-145 complex significantly
Figure 3 Presence of markers of CSC and their growth and
differentiation in xenografts derived from parental HT-29 or CR
HT-29 cells. qRT-PCR showing relative expression of CD44, CK20,
β-Catenin, PDCD4 and Sox2 in xenografts derived from parental
HT-29 or CR HT-29 cells. The data represent means ± SD of three
independent experiments, *P < 0.001, compared to the control.
Figure 4 miR-145 reduces tumorigenic potential of chemo-resistant (CR)
colon cancer HT-29 cells in SCID mice. (A) administration of PEI/miR-145
complexes suppresses xenograft growth in SCID mice. CR HT-29 cells
(2.5 × 105 cells) were injected with 50% Matrigel. Once palpable tumors
developed (~3 weeks), the treatment (i.p.; weekly) was initiated. Upper
panel shows intact xenograft tumor after treatment with PEI/miR-145 or
the corresponding controls, and the lower panel shows the relative levels
of miR-145 in the tumor after treatment with PEI/miR-145 or the
corresponding controls. (B) qRT-PCR showing relative expression of CD44,
CK20, β-Catenin, PDCD4 and Sox2 in tumors derived from CR HT-29 cells
after treatment with PEI/miR-145 (miR145 Treated ) or the corresponding
controls (Control). The data represent means ± SD of three independent
experiments, *P< 0.001, compared to the control.
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treated controls (Figure 4A). The relative level of miR-145
in the tumor of SCID mice injected with miR-145 was
about 50% higher than the control tumor (Figure 4A;
lower panel).
At the end of the experiment, a small portion of the
tumors from CR-HT-29 cells and those treated with
(PEI)/miRNA-145 or vehicle complex was used for RNA
extraction and analyzed for the expression of various
markers of CSC growth and differentiation by real time
PCR. The expression of CD44, β-catenin and SOX2 was
decreased by 45%, 34% and 36%, and PDCD4 and CK20
was increased significantly by 10% and over 4000%, re-
spectively, in CR-HT-29 xenografts from (PEI)/miRNA-
145 complex-treated xenograft, compared to those
fromed by vehicle- treated (control) CR HT-29 cells
(Figure 4B). These results indicate that administration of
miR-145 greatly decreases CSC proliferation and induces
differentiation leading to suppression of tumor growth
in SCID mice.
Discussion
Although many factors may contribute to colorectal cancer,
chemo-resistance and relapse of cancer and metastasis, it is
reasonable to speculate that CSCs play critical role in these
processes. Our current data further suggest that the tumor
suppressor miR-145, oncomiR miR-21 and their networks
are critically involved in regulating these events.
Earlier, we reported that exposure of colon cancer HCT-
116 or HT-29 cells to the combination of 5-Fluorouracil
(5-FU) and Oxaliplatin (Ox), the backbone of colorectal
cancer chemotherapy, inhibited their growth and led to
enrichment of CSC/CSLC phenotype, where the levels of
miR-21 were greatly increased indicating a potential role forthis miR in regulating CSCs/CSLCs [7,8]. In addition, we re-
ported miR-21 to induce stemness of colon cancer cells by
down-regulating TGFβR2 and that down-regulation of miR-
21 induces differentiation of CR colon cancer cells and en-
hances susceptibility to therapeutic regimens [8,17].
We also demonstrated that miR-21 regulates CSC func-
tion as well as its growth and differentiation by modulating
its direct targets such as TGFβR2, PDCD4 and PTEN, as re-
ported earlier [8,17,19]. Our current data show that miR-21
also regulates the expression of the tumor suppressor miR-
145. The latter is supported by the following observations:
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regulated in colon cancer CR-HCT-116 cells, highly
enriched in CSCs/CSLCs; (b) forced expression of miR-21
through transfection of mature miR-21 in colon cancer
HCT-116 cells decreases the expression of miR-145; (c)
knock-down of miR-21 by anti-miR-21 increases miR-145 in
CR colon cancer cells. These results indicate that miR-21
negatively regulates the expression of miR-145 in colon can-
cer cells. On the other hand, miR-21 can be decreased by
elevating the levels of miR-145 through transfection of ma-
ture miR-145 in parental and CR colon cancer cells. These
data further suggest that a negative feedback exists between
miR-21 and miR-145.
miR-145 is a p53-regulated gene. p53 can induce its tran-
scription and enhance the post-transcriptional maturation
of miR-143/miR-145 cluster [15,20] in response to DNA
damage by interacting with the Drosha processing complex
[21]. Activated Ras can suppress miR-143/145 cluster tran-
scription through Ras-responsive element-binding protein
(RREB1), which represses the miR-143/145 promoter [22].
Hatley and colleagues have reported that miR-21 increases
RAS signaling activity and therefore leads to repression of
the miR-143/145 cluster [23]. These reports support our
data and further demonstrate the mechanism by which
miR-21 negatively regulates tumor suppressor miR-145.
Down-regulation of miR-145 has been found in multiple
tumors including colon, breast, prostate, pancreas etc.
[14,15]. In fact, miR-145 has been well documented as a
tumor suppressor gene because it negatively regulates mul-
tiple oncogenes such as Myc, K-Ras, IRS-1, ERK5 [15,24].
Moreover, miR-145 negatively regulates junctional cell adhe-
sion molecule (JAM-A), fascin and MUC1 and suppresses
breast cancer cell motility and invasiveness [25,26]. miR-145
also inhibits colon cancer cells’ proliferation and sensitizes
them to 5-fluorouracil by targeting oncogenic FLI1 [27].
miR-21 expression is regulated at multiple levels, in-
cluding transcription and post-transcriptional process-
ing. Talotta et al. [28] have reported that the miR-21 is
induced by AP1 in response to Ras. They have also dem-
onstrated that PDCD4, a pro-apoptotic gene and the tar-
get of miR-21, is a negative regulator of AP1. The miR-
21-mediated down-regulation of PDCD4 is essential for
the maximal induction of AP1 activity in response to
Ras. These data reveal a mechanism of positive auto-
regulation of the AP1 complex in Ras transformation
and disclose the function of oncomiRs as critical targets
and regulators of AP1 in tumorigenesis [29]. Kern et al.
[30] also showed that EGF/Ras efficiently induced the
miR-21 primary transcript, but this does not rapidly and
simply translate into higher mature miR-21 levels.
In view of these reports together with our current ob-
servations prompted us to hypothesize that the negative
feedback between miR-21 and miR-145 mediated by Ras
signaling pathway plays a crucial role in the induction ofCSC proliferation or/and differentiation in CR colon cancer
cells, as depicted in Figure 5A. Restoration of miRs level by
increasing miR-145 or decreasing miR-21 can dislodge Ras
mediated feedback between miR-145 and miR-21 and
inhibit tumor growth. Indeed, this hypothesis has been sup-
ported by our in vitro (Figure 5B-D) and in vivo experiments
(Figure 4). In the in vitro studies, downregulation of k-Ras
in CR colon cancer cells was achieved by transfection with
corresponding siRNA and the controls with scrambled
siRNA. The protein as well as mRNA levels of k-Ras were
substantially reduced (70–80% reduction), as determined by
Western blot and qRT-PCR analyses, when compared with
the corresponding controls (Figure 5B). Down-regulation of
k-Ras in CR HT-29 cells, that caused a 45% increase in miR-
145, produced a 35% reduction in miR-21, when compared
with the corresponding controls (Figure 5C). Forced expres-
sion of miR-21 in k-Ras downregulated CR-HT-29 cells re-
sulted in 1-fold increase in miR-145 (Figure 5D). But,
increasing the levels of miR-145 in k-ras downregulated CR-
HT-29 cells resulted in no significant reduction in miR-21,
compared with corresponding control (Figure 5D). These
observations are in contrast to those depicted in Figure 2D,
where are show that in cell with intact k-Ras, downregula-
tion of miR-21 produced 6-fold augmentation of miR-145,
forced expression of miR-145 resulted in 70% reduction in
miR-21. These observations suggest that k-Ras mediates the
negative feedback between the tumor suppressor miR-145
and oncomiR miR-21 in CR colon cancer cells. This infer-
ence is further supported by our in vivo experiments which
demonstrate that increase of miR-145 or inhibition of miR-
21 by injecting PEI mediated chemically engineered modi-
fied single-stranded RNA or analogues complementary to
miRNA which are efficient, specific and long-lasting replace-
ments or silencers of endogenous miRNAs in mice [24,31]
leads to suppression of xenograft growth in SCID mice. The
growth inhibition was associated with decreased prolifera-
tion of CSCs and induction of their differentiation, as evi-
denced by reduction in expression of CD44 and induction
of CK20 following upregulation of miR-145 or down-
regulation of miR-21.
Conclusions
Our current observations suggest that dysregulation
of miR-21 and miR-145 plays a central role in the
growth of CSCs in chemo-resistant colon tumors by
regulating a network of genes that are critically involved
in tumor progression, metastasis, and relapse of colo-
rectal cancer.
Materials and methods
Cell lines and cell cultures
Human colon cancer HCT-116 and HT-29 cells were ob-
tained from the American Type Culture Collection (ATCC,
Rockville, MD). They were expanded and frozen in aliquots.
Figure 5 The feedback circuits between miR-21 and miR-145. (A) Schematic representation of circuits between miR-21 and miR-145, and themselves in
cancer stem cells. Herein, it is suggested that miR-21 represses miR-145 transcription by stimulating Ras activity that causes RREB1 to repress miR-145
transcription, and that miR-145 inhibits miR-21 transcription through knockdown target Ras (K-RAS) and decreased AP1, the main transcription factor of
miR-21. In the miR-21 positive feedback loop, miR-21 is auto-upregulated via indirect upregulation of AP1. In the miR-145 positive feedback loop, miR145
increases its transcription via knock-down Ras and RREB1, the transcription repressor of miR-145. Pleuripotency factors Sox2, Nanog and Oct4 are the direct
targets of miR-145. (B) Real-time qRT-PCR and Western blot analysis showing down-regulation of k-Ras following transfection with k-Ras siRNA for 48 h,
compared to the corresponding scrambled siRNA transfected control cells. β-actin was used as a loading control. (C) qRT-PCR showing down-regulation of
k-Ras in CR HT-29 cells produces reduction in miR-21 and increases in miR-145 expression, when compared with the corresponding controls (D) qRT-PCR
showing relative expression of miR-21 and miR-145 in k-ras-downregulated CR HT-29 cells at 48 h following transfection of mature miR-145 or miR-21. All the
qRT-PCR data represent means ± SD of three independent experiments; *P< 0.001, compared to the control.
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were maintained in Dulbecco's modified Eagle medium
(DMEM; 4.5 g/L d-glucose) supplemented with 10% FBS
(Invitrogen, Grand Island, NY) and 1X antibiotic/antimy-
cotic (Invitrogen, Grand Island, NY) in tissue culture
flasks, 5-Fluorouracil and Oxaliplatin (FuOx) resistant
[chemo-resistant (CR)] colon cancer HCT116 and HT29
cells were generated as described earlier [7,8] in our la-
boratory and were maintained in normal culture medium
containing 2× FuOx (50 μM 5-Fu + 1.25 μM Ox) in tissue
culture flasks in a humidified incubator at 37°C in an
atmosphere of 95% air and 5% carbon dioxide. The
medium was changed two times a week, and cells were
passaged using 0.05% trypsin/EDTA (Invitrogen, Grand
Island, NY).Western blot analysis
Western blot analysis was performed according to our
standard protocol [32,33]. Briefly, the cells were solubi-
lized in lysis buffer and the protein concentration was
determined by the Bio-Rad Protein Assay kit (Bio-Rad,
Hercules, CA). The proteins were separated by SDS-
PAGE and transferred to PVDF membranes (Millipore).
The membranes were incubated overnight at 4°C with
primary antibodies after blocking. The membranes were
subsequently washed and incubated with appropriate
secondary antibodies. The protein bands were visualized
by enhanced chemiluminescence (ECL) detection sys-
tem (Amersham, Piscataway, NJ). Whenever appropri-
ate, the membranes were stripped and re-probed with
β-actin for verification of protein loading.
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siRNA in colon cancer cells
For transfection of miR-21/145, anti-miR-21 or/and
siRNA in the CR-HCT-116 or CR-HT-29 cells, Lipofecta-
mine 2000 transfection reagent (Invitrogen Corp.) and
serum-free Opti-MEM (Invitrogen Corp.) medium were
prepared according to the manufacturer's instructions.
Briefly, the cells were plated in six-well tissue culture
plates with normal growth medium and incubated over-
night to achieve 40–60% confluence. Next day, the
medium was removed, washed with serum-free Opti-
MEM (Invitrogen Corp.) medium prior to adding the
complexes containing 100 pmol of scrambled (control), k-
Ras siRNA (Integrated DNA Technologies, Coralville, IA)
or/and pre-miR-145, pre-miR-21. After 2 days of transfec-
tion, the cells were collected and analyzed for protein ex-
pression of k-Ras using western blot and for quantitation
of miRNA-21 and miR-145 by qRT-PCR according to our
standard protocol.
Isolation of RNA and quantitative polymerase chain
reaction analysis
Total RNA was extracted from different cells using
RNA-STAT solution (Tel Test, Friendswood, TX)
according to the manufacturer's instructions. The total
RNA was treated with DNase I and purified with
phenol-chloroform. RNA concentration was measured
using a NanoDrop 2000C spectrophotometer.
Quantitative reverse transcription-polymerase chain re-
action (qRT-PCR) was performed using the GeneAmp
RNA PCR Kit (Applied Biosystems, Foster City, CA). 5 μl
of cDNA products were amplified with SYBR Green
Quantitative PCR Master Mix (Applied Biosystems). PCR
primers used were as follows: CD44, forward: 5′-aaggtggag
caaacacaacc-3′, reverse: 5′-actgcaatgcaaactgcaag-3′; CK-20,
forward: 5′-tgaagagctgcgaagtcaga-3′ and reverse: 5′-gaagtc
ctcagcagccagtt-3′, β-Catenin forward: 5'-ggaaggtctccttggga
ctc-3' and reverse: 5'-ataccacccacttggcagac-3'; PDCD4, for-
ward: 5'-ggtgggccagtttattgcta-3' and reverse: 5'-cggtacccttatc-
cagagca-3'; Sox2, forward: 5'-aaccccaagatgcacaactc-3' and
reverse: 5'-gcttagcctcgtcgatgaac-3'; k-Ras, forward: 5'-tgtgg
tagttggagctggtg-3' and reverse: 5'-tccaagagacaggtttctcca-3'; β-
actin forward: 5′-cccagcacaatgaagatcaa-3′ and reverse 5′-ac
atctgctggaaggtggac-3′. Reactions were carried out in Applied
Biosystems 7500 Real-Time PCR System; The running con-
ditions for PCR were as follows: for activating the DNA
polymerase, hot start was performed for 10 min at 95°C,
and then cycling at 95°C for 15 s and 60°C for 1 min for a
total of 40 cycles.
Quantitation of miRNA-21 and miR-145
TaqMan microRNA assays were used to quantitate miR-
21 and miR-145 in different colon cancer cells according
to the manufacturer’s instructions (Applied Biosystems,Foster City, CA). Briefly, cDNA synthesis was carried out
with the TaqMan MicroRNA reverse transcription kit
(Applied Biosystems). The miRNA reverse transcription-
PCR (RT-PCR) primers for miR-21, miR-145 and en-
dogenous control RNU6B were purchased from Applied
Biosystems. Real-time quantitative RT-PCR (qRT-PCR)
analysis was carried out using Applied Biosystems 7500
Real-time PCR System. The PCR mix containing TaqMan
2× Universal PCR Master Mix were processed as follows:
95°C for 10 min and then 95°C for 15 s, 60°C for 60 s for
up to 40 cycles. Signal was collected at the endpoint of
every cycle. The gene expression ΔCT values of miRNAs
from each sample were calculated by normalizing with in-
ternal control RNU6B and relative quantitation values
were plotted.
Generation of miR-145 over-expressing HCT-116 cells
pCMV-miR-145 plasmid carrying pre-microRNA-145 and
250–300 nts up and down-stream flanking sequence (Ori-
gene, Nockville, MD) or empty vector DNA alone (pCMV)
was transfected into HCT-116 cells by Lipofectamine™
2000 reagent according to the manufacturer's instructions
(Invitrogen Corp, CA). Several independent sublines (col-
onies) were generated over 8–10 wk of the selection period
in the presence of 0.6 mg/ml G418 (Neomycin). Colonies
were picked at random and grown as individual cell lines in
the presence of 0.4 mg/ml G418. Each cell line was sub-
jected to RT-PCR analysis to evaluate miR-145 expression.
Formation of colonospheres and Extreme limiting dilution
analysis
The ability of miR-145-overexpressing and parental HCT-
116 cells to form spheres in suspension was evaluated as
described previously [18]. Briefly, primary colonospheres
were generated by incubating the limited number of
pCMV and miR-145 stably transfected HCT-116 cells at a
concentration of 1000 cells per 500 μL in serum-free stem
cell medium (SCM) containing DMEM/F12 (1:1) supple-
mented with B27 (Life Technologies, Gaithersburg, MD),
20 ng/ml EGF (Sigma, St Louis, MO), 10 ng/ml fibroblast
growth factor (Sigma), and antibiotic-anti-mycotic in 24-
well plates (Corning Inc, Lowell, MA) for 10 days. The
formed colonospheres were centrifuged (1000 rpm), disso-
ciated with 0.05% trypsin/EDTA and reseeded in SCM.
The single-cell suspension derived from colonospheres
that have undergone 15 or more serial passages were used
for all experiments.
Self-renewing/regeneration abilities of the spheres, derived
from pCMV and miR-145 stably transfected HCT-116 cells,
were analyzed for secondary colonospheres formation in the
following manner. Primary colonospheres formed over a
period of ten days in SCM containing DMEM/F12 (1:1)
were collected by centrifugation, dissociated with 0.05%
trypsin/EDTA, and subsequently passed through a 40 μM
Yu et al. Molecular Cancer  (2015) 14:98 Page 9 of 10sieve to obtain single cell suspensions. An equal number of
cells from primary colonospheres culture were plated (100
cells/500 μL in SCM) in ultra low-attachment wells. The
secondary colonospheres formed after five days were re-
corded for their number and size by light microscopy.
Extreme limiting dilution analysis (ELDA) was per-
formed essentially according to Hu and Smyth with slight
modifications as described by us [18,34]. Briefly, single cell
suspension obtained from adherent miR-145-expressing
HCT-116 and vector-transfected (control) HCT-116 cells
were plated at concentrations of 200, 20 and 2 cells per
100 μl SCM (24 well for each dilution) in 96-well plates
and incubated for 5 days. At the end of 5 days, the num-
ber of wells showing formation of colonospheres was
counted. The frequency of sphere formation in a particu-
lar cell type was determined using ELDA webtool at
http://bioinf.wehi.edu.au/software/elda.SCID mice xenografts
The research protocol was approved by Wayne State
University and the VA Medical Center Institutional Ani-
mal Care and Use Committees. Four-week-old female
ICR/severe combined immunodeficient mice (SCID),
obtained from Taconic Laboratory (Germantown, NY)
were used for these studies.
To determine the tumorigenic potential of miR-145 over-
expressing HCT-116 cells, SCID mice were subcutaneously
(s.c.) injected with ∼ 2.5 × 105 HCT-116 cells that were stably
transfected with pCMV/miR-145 or pCMV (control).
To further determine whether and to what extent forced
expression of miR145 or down-regulation of miR-21 by
anti-miR21 would affect the tumorigenic potential of
colon cancer cells, SCID mice were subcutaneously
injected either with ~ 2.5 × 105 CR HCT-116 or CR HT-
29 cells suspended in 100 μl Matrigel. Once palpable tu-
mors were formed, SCID mice bearing xenografts were
treated with PEI/miRNA-145, PEI/anti-miRNA-21 com-
plexes or PEI/control once a week by i.p. injection of
0.45 nmol (6 μg) for 3 weeks [24]. Tumor measurements
were carried out at multiple time points during the experi-
mental period. The experiment was repeated 3 times with
3–5 mice in each group. Mice were weighed regularly to
monitor their well being, and the tumor volumes were es-
timated as follows: volume (mm3) = (L ×W2) / 2, where L
and W are the tumor length and width (in mm),
respectively.Statistical analysis
Unless otherwise stated, data are expressed as mean ± SEM.
Wherever applicable, the results were analyzed using ana-
lysis of variance followed by Fisher protected least signifi-
cant differences or Scheffé test. p < 0.05 was designated as
the level of significance.Abbreviations
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